Skip to content
Trial Agents

Clinipace

Clinipace is recorded as a service provider in 29 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.

29distinct trials
24recorded service labels
1trials with learnings

Data snapshot: 2026-10-09 · About the data

Clinical trial experience

Showing 20 of 29 trials · Latest update first

PHOENIX - ECP: A Phase 2, Randomized, Controlled, Open-label, Multicenter Study to Evaluate the Efficacy and Safety/Tolerability of Extracorporeal Photopheresis (ECP) Versus Best Available Therapy (BAT) for the Treatment of Immune-related Colitis and/or Hepatitis with Inadequate Response to Corticosteroids in Participants with Unresectable or Metastatic Melanoma Treated with Immune Checkpoint Inhibitors (ICI)

Sponsor Therakos Europe Limited

Start (EU)
Not reported
Latest update
Estimated end

A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients with Selected Advanced Solid Tumors

Sponsor ADC Therapeutics S.A.

Start (EU)
Latest update
Estimated end
Operational learnings available4 trial-level findings · Read insights
  • Enrollment was substantially below plan: 30 patients were enrolled globally versus approximately 132 planned.
  • Part 1 enrolled 26 of 92 planned patients and Part 2 enrolled 4 of 40 planned patients; backfilling was not opened.
  • The study operated at 13 sites: 4 in Spain, 2 in the United Kingdom, and 7 in the United States.
  • Following the single response observed in cholangiocarcinoma during Part 1, Part 2 enrolled only patients with cholangiocarcinoma; no response was observed in Part 2.

These findings describe the trial, not the service provider’s performance or responsibility.

A Phase 2, multicenter, randomized, open-label trial of GEN1046 as monotherapy and in combination with Pembrolizumab in subjects with relapsed/refractory metastatic non-small cell lung cancer after treatment with standard care therapy with a immune checkpoint inhibitor.

Sponsor Genmab A/S

Start (EU)
Latest update
Estimated end

ORACLE: A long-term follow-up study to evaluate the safety of GT005 in participants with geographic atrophy, secondary to age-related macular degeneration treated in a Gyroscope-sponsored antecedent study.

Sponsor Novartis Pharma AG

Start (EU)
Latest update
Estimated end

MLS-101-901: An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hypertension

Sponsor Mineralys Therapeutics Inc.

Start (EU)
Latest update
Estimated end

A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Sponsor Dizal Pharmaceutical Co. Ltd.

Start (EU)
Latest update
Estimated end

A Randomized, Open-Label, Multicenter, Global, Phase 2 Trial to Evaluate the Efficacy and Safety of Epcoritamab (GEN3013; DuoBody®-CD3×CD20) as Monotherapy or in Combination with Lenalidomide as First-Line Therapy for Anthracycline-Ineligible Subjects with Diffuse Large B-Cell Lymphoma

Sponsor Genmab A/S

Start (EU)
Latest update
Estimated end

Questions about this trial experience

What services are recorded for Clinipace?

The 2026-10-09 snapshot links Clinipace to 29 distinct CTIS trials. Recorded services include Data management, Project management, Clinical monitoring, Electronic data capture, among 24 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.

Which therapeutic areas and study phases are recorded for Clinipace?

The most frequently recorded therapeutic areas are Haematological Malignancies, Solid Tumor Oncology, Hepatology, Gastroenterology. Recorded phases include Phase 2, Phase 1, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.

In which countries are trials linked to Clinipace conducted?

The linked trials record locations in 19 countries, including Spain, France, Italy, Poland, Germany. These are trial locations, not confirmed office locations or countries where Clinipace delivered services.

What can this page tell me about Clinipace's trial experience?

Browse 29 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.

About this data & company names

One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.

Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.

Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 3 recorded name variants under Clinipace. Legacy brands remain separate unless explicitly matched in the name registry.

View recorded company names
  • Clinipace Global Limited
  • Clinipace GmbH
  • Clinipace Inc.

Never miss a new clinical trial insight

We continuously analyze new and updated clinical trial data and publish practical, evidence-led reports for clinical leaders.

By entering your email, you agree to receive emails from Trial Agents. You can unsubscribe anytime.